Compare Altria Group Inc (MO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs TG Therapeutics Inc — how do they compare? Altria Group Inc trades at $64.98 (market cap $108.58B), while TG Therapeutics Inc trades at $50.44 (market cap $7.64B). The key difference: Altria Group Inc is far larger — about 14.2× TG Therapeutics Inc's market cap, and Altria Group Inc pays a 6.52% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MO | TGTX | |
|---|---|---|
Market Cap | $108.58B | $7.64B |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $59.06 |
52-Week Low | $54.72 | $26.94 |
Enterprise Value | $130.79B | $7.84B |
Dividend Yield | 6.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $65.54, down 4.11% amid bearish technical signals and mixed earnings performance. The stock shows strong fundamentals with a 39% net income margin and attractive 6.3% dividend yield, though cigarette volume declines persist. Recent Q2 2026 earnings missed expectations, triggering price weakness and multiple legal investigations into potential securities violations. Analyst consensus remains positive with 61.5% buy ratings and $67 price target, but technical indicators suggest near-term pressure with support at $62-65.
MO presents a value opportunity for income investors with its high yield and reasonable P/E of 13.7, though regulatory risks and declining traditional tobacco business create headwinds. The smoke-free product expansion offers growth potential, but legal uncertainties and volume erosion require careful monitoring. Current levels near support provide entry points for dividend-focused investors willing to accept sector-specific risks.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
